Transform the future of cancer screening with Cancerguard®
One simple blood draw could help you detect cancer even in early stages and impact more lives.
~70% of annual cancer cases and deaths have no recommended screening4
With ~600,000 deaths in the US every year, cancer is the 2nd deadliest disease.2
Recommended screening only catches 1 in 7 cancers‡,5
Only 4 types of cancer have recommended screening options6
The Cancerguard test dramatically expands your screening power
Helps find the deadliest cancers
Cancerguard can help detect cancer types responsible for the majority of annual cancer diagnoses in the U.S. including the ones that are hardest to find.
With Cancerguard, you can expand your screening capabilities to enable more comprehensive proactive care.
Catching cancer earlier can change everything. The Cancerguard test found 1 in 3 early-stage cancers in a large test development study.
You can help your patients move forward with confidence--and stay one step ahead of even the most aggressive cancers.
With high specificity, the Cancerguard test delivers actionable results.
Low false positive rates, which minimize unnecessary imaging and follow up, mean you can do more for your patients.
Multiple biomarker classes.
Actionable results.
The first test of its kind to combine DNA methylation and protein biomarkers1
- Analyzing multiple biological signals casts a wider net for detecting cancer in its early stages.
- Our multi-biomarker class approach boosts detection, especially for early stage cancers.
7 - The Cancerguard test can help detect 50+ cancer types and subtypes.
8
Designed to minimize unnecessary follow-ups
Cancerguard was designed to streamline the diagnostic workflow after a patient receives a positive result.
Expert-designed imaging workflow
Developed by radiologists and health system experts to ease implementation
Less guesswork. Greater efficiency.
An imaging-based diagnostic workflow designed to help you provide consistent, reliable follow-up care for patients
Showed a ~30% reduction in diagnostic burden
Fewer procedures vs. molecular methods on modeling outcomes
Imaging resolution workflow is based on published expert clinician opinion and results from an exploratory, prospective, interventional modeling study. It is not a replacement for clinical standard of care. There are no established guidelines for imaging following a positive Cancerguard test result. Providers should use their clinical judgement and experience when deciding how to diagnose or treat patients.
Trusted guidance to ease patient anxiety
When patients test positive, we're here to help them. Our positive results services provide patients with hands-on guidance for their next steps.
Our Care Navigators can act as a patient’s personal guide after a positive test result and cover things like:
- Finding locations for follow-up imaging and testing
- Providing eligibility details for our Patient Imaging Reimbursement Program
- Help assess and reduce barriers to getting follow-up care
Coverage of follow-up imaging after a positive result varies based on insurance plans and a patient’s unique situation. If a patient has a positive test result, our imaging reimbursement program can help reduce the financial impact for eligible patients, so they can stay focused on their health. Patients must apply and eligibility depends on program qualifications and is not guaranteed.
The Imaging Reimbursement program will not reimburse any covered imaging costs, including copay, coinsurance and/or deductible amounts determined by insurance.
Results designed for clarity
Patients’ results are ready about 2 weeks after our lab receives their blood sample. Results are either positive or negative and can help you determine next steps. In rare cases, an invalid result can occur.
Negative result
Positive result
False negative and false positive results can occur. A false negative result means the test did not find signals of cancer, but a person does have cancer. A false positive result means the test found signals of cancer, but a person doesn’t have cancer.
Built by the best
With over two decades of experience helping millions navigate life-changing cancer diagnoses, Exact Sciences is redefining cancer screening with Multi-Cancer Early Detection (MCED) testing.
We’re the proud makers of:
Partnering with the brightest minds in cancer research
Exact Sciences has been leading the development of MCED testing in collaboration with the broader cancer community. We work with patient advocacy groups, forums, and researchers at premier institutions to help to shape the future of cancer detection.
Get started today
- Interest in health and wellness: Proactive patients who stay up to date with routine care and screenings or express interest in new clinical technologies
- Habits and environment: Patients with increased risk factors such as smoking, alcohol use, or obesity.
1 - Medical and family history: Certain conditions that could raise a patient's concern or risk of cancer.
1 - History of cancer: Patients who have not had cancer or are 3+ years post a cancer diagnosis.
Three ways to use biomarkers to gain insight
Cancerguard is one of three distinct tests we offer that look for cancer in different ways. Here’s what sets them apart.
Multi-Cancer Early Detection (MCED) test
Hereditary Cancer Test
(HCT)
Molecular Residual Disease (MRD) test
Have questions?
Footnotes and references
Important Information about the Cancerguard Test
Rx only. The Cancerguard® test is indicated for use in adults ages 50-84 with no known cancer diagnosis in the last three years. It detects alterations in circulating tumor DNA and tumor-associated protein levels which are commonly associated with cancer. The test does not detect all cancers and is not a replacement for existing recommended cancer screening or diagnostic modalities for cancer. Current recommended screening for cancer should also be followed. The test is not indicated for screening of breast and prostate cancer and was not evaluated for the detection of pre-cancerous lesions. Due to the potential for follow-up imaging with IV contrast CT after a positive test result, careful consideration should be given before ordering the Cancerguard test for patients with a history of adverse reactions to iodine based IV contrast or for women who are, may be, or plan to become pregnant. Results should be interpreted in the context of a patient’s medical history, clinical signs, and symptoms. A negative result does not rule out the presence of cancer of any type. A positive Cancerguard® test result means that the blood test identified a cancer signal that may indicate the presence of cancer. This result alone does not confirm the presence of cancer. Further clinical evaluation by a healthcare provider (which may include blood tests such as complete blood count and comprehensive metabolic panel) and follow-up imaging are needed to locate and confirm a diagnosis of cancer or determine that cancer is not present. While there are no established guidelines for imaging following a positive Cancerguard test result, there is a published follow-up workflow based on expert clinician opinion and results from an exploratory, prospective, interventional study [Kisiel et al Life (Basel) 2024 Jul 24; Lennon et al, Science, 2020]. The proposed workflow in the Kisiel et al publication includes an intravenous-contrast enhanced computed tomography (IV contrast CT of chest, abdomen/pelvis, and soft-tissue neck) and if necessary, positron emission tomography-computed tomography (18F FDG PET-CT) from the skull-base to mid-thigh. Alternative follow-up procedures (e.g. targeted imaging, endoscopic procedures, CT without IV- contrast) may be appropriate in the context of the patient’s medical history and clinical evaluation [Lennon et al, Science, 2020]. False positive and false negative test results can occur.
The Cancerguard test was developed, and the performance characteristics validated by Exact Sciences Laboratories following College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) regulations. This test has not been cleared or approved by the US Food and Drug Administration. The test is performed at Exact Sciences Laboratories. Exact Sciences Laboratories is accredited by CAP, certified under CLIA regulations, and qualified to perform high-complexity clinical laboratory testing.